NCT07531719 is a clinical trial in Spinal Muscle Atrophy, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT07531719?

NCT07531719 is sponsored by Hoffmann-La Roche.

What condition does NCT07531719 study?

NCT07531719 studies Spinal Muscle Atrophy.

Is NCT07531719 still recruiting?

NCT07531719 is currently not yet recruiting. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT07531719

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)

Not yet recruiting Last updated 15 April 2026

What this trial tests

trial in Spinal Muscle Atrophy in 30 participants. Not yet recruiting.

Timeline

15 April 2026

Primary endpoint
1 March 2028

1 March 2029

Quick facts

Lead sponsor	Hoffmann-La Roche
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	30
Start date	15 April 2026
Primary completion	1 March 2028
Estimated completion	1 March 2029

Conditions studied

Spinal Muscle Atrophy — all drugs for Spinal Muscle Atrophy →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

Under 5, any sex, with Spinal Muscle Atrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multicenter, non-interventional, prospective study with a retrospective component aims to evaluate the real-world clinical outcomes, safety profile, and motor function improvements of Risdiplam treatment in participants with Type I and Type II Spinal Muscle Atrophy over 24 months of treatment. The study will allow retrospective collection of medical history data and previous participants visits from the medical records.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07531719 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07531719.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing